Frontiers in Genetics (Nov 2019)
Epigenetics of Bladder Cancer: Where Biomarkers and Therapeutic Targets Meet
- Victor G. Martinez,
- Victor G. Martinez,
- Ester Munera-Maravilla,
- Ester Munera-Maravilla,
- Ester Munera-Maravilla,
- Alejandra Bernardini,
- Alejandra Bernardini,
- Alejandra Bernardini,
- Carolina Rubio,
- Carolina Rubio,
- Carolina Rubio,
- Cristian Suarez-Cabrera,
- Cristian Suarez-Cabrera,
- Cristina Segovia,
- Cristina Segovia,
- Iris Lodewijk,
- Iris Lodewijk,
- Marta Dueñas,
- Marta Dueñas,
- Marta Dueñas,
- Mónica Martínez-Fernández,
- Jesus Maria Paramio,
- Jesus Maria Paramio,
- Jesus Maria Paramio
Affiliations
- Victor G. Martinez
- Biomedical Research Institute I + 12, University Hospital 12 de Octubre, Madrid, Spain
- Victor G. Martinez
- Molecular Oncology Unit, CIEMAT (Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas), Madrid, Spain
- Ester Munera-Maravilla
- Biomedical Research Institute I + 12, University Hospital 12 de Octubre, Madrid, Spain
- Ester Munera-Maravilla
- Molecular Oncology Unit, CIEMAT (Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas), Madrid, Spain
- Ester Munera-Maravilla
- Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain
- Alejandra Bernardini
- Biomedical Research Institute I + 12, University Hospital 12 de Octubre, Madrid, Spain
- Alejandra Bernardini
- Molecular Oncology Unit, CIEMAT (Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas), Madrid, Spain
- Alejandra Bernardini
- Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain
- Carolina Rubio
- Biomedical Research Institute I + 12, University Hospital 12 de Octubre, Madrid, Spain
- Carolina Rubio
- Molecular Oncology Unit, CIEMAT (Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas), Madrid, Spain
- Carolina Rubio
- Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain
- Cristian Suarez-Cabrera
- Biomedical Research Institute I + 12, University Hospital 12 de Octubre, Madrid, Spain
- Cristian Suarez-Cabrera
- Molecular Oncology Unit, CIEMAT (Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas), Madrid, Spain
- Cristina Segovia
- Biomedical Research Institute I + 12, University Hospital 12 de Octubre, Madrid, Spain
- Cristina Segovia
- Molecular Oncology Unit, CIEMAT (Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas), Madrid, Spain
- Iris Lodewijk
- Biomedical Research Institute I + 12, University Hospital 12 de Octubre, Madrid, Spain
- Iris Lodewijk
- Molecular Oncology Unit, CIEMAT (Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas), Madrid, Spain
- Marta Dueñas
- Biomedical Research Institute I + 12, University Hospital 12 de Octubre, Madrid, Spain
- Marta Dueñas
- Molecular Oncology Unit, CIEMAT (Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas), Madrid, Spain
- Marta Dueñas
- Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain
- Mónica Martínez-Fernández
- Genomes & Disease Lab, CiMUS (Center for Research in Molecular Medicine and Chronic Diseases), Universidade de Santiago de Compostela, Santiago de Compostela, Spain
- Jesus Maria Paramio
- Biomedical Research Institute I + 12, University Hospital 12 de Octubre, Madrid, Spain
- Jesus Maria Paramio
- Molecular Oncology Unit, CIEMAT (Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas), Madrid, Spain
- Jesus Maria Paramio
- Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain
- DOI
- https://doi.org/10.3389/fgene.2019.01125
- Journal volume & issue
-
Vol. 10
Abstract
Bladder cancer (BC) is the most common neoplasia of the urothelial tract. Due to its high incidence, prevalence, recurrence and mortality, it remains an unsolved clinical and social problem. The treatment of BC is challenging and, although immunotherapies have revealed potential benefit in a percentage of patients, it remains mostly an incurable disease at its advanced state. Epigenetic alterations, including aberrant DNA methylation, altered chromatin remodeling and deregulated expression of non-coding RNAs are common events in BC and can be driver events in BC pathogenesis. Accordingly, these epigenetic alterations are now being used as potential biomarkers for these disorders and are being envisioned as potential therapeutic targets for the future management of BC. In this review, we summarize the recent findings in these emerging and exciting new aspects paving the way for future clinical treatment of this disease.
Keywords